Ibudilast: Difference between revisions

Ibudilast
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Newer edit →

Revision as of 04:04, 13 February 2025

Ibudilast is a phosphodiesterase inhibitor that has been investigated for its potential use in treating various neurological disorders. It is known for its anti-inflammatory and neuroprotective properties.

Mechanism of Action

Ibudilast works primarily by inhibiting the activity of phosphodiesterase (PDE) enzymes, particularly PDE-4 and PDE-10. This inhibition leads to an increase in intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important secondary messengers in cellular signaling pathways. By modulating these pathways, ibudilast exerts its anti-inflammatory and neuroprotective effects.

Therapeutic Uses

Ibudilast has been studied for its potential benefits in several neurological conditions, including:

Multiple Sclerosis

Ibudilast has shown promise in the treatment of multiple sclerosis (MS), a chronic autoimmune disease that affects the central nervous system. It may help reduce inflammation and slow the progression of the disease.

Neuropathic Pain

The drug has also been investigated for its ability to alleviate neuropathic pain, which is pain caused by damage to the nervous system. Its anti-inflammatory properties may help reduce pain and improve quality of life for patients.

Drug Addiction

Research has explored the use of ibudilast in treating drug addiction, particularly for substances such as methamphetamine and opioids. It may help reduce cravings and withdrawal symptoms.

Side Effects

Common side effects of ibudilast include nausea, headache, and dizziness. More serious side effects are rare but can include liver dysfunction and allergic reactions.

Pharmacokinetics

Ibudilast is administered orally and is well absorbed from the gastrointestinal tract. It is metabolized in the liver and excreted primarily in the urine. The drug has a half-life of approximately 19 hours, allowing for once or twice daily dosing.

Research and Development

Ongoing research is exploring the full potential of ibudilast in various neurological and inflammatory conditions. Clinical trials are being conducted to better understand its efficacy and safety profile.

Related pages

@@ Line 1: / Line 1: @@
-'''Ibudilast''' is a [[phosphodiesterase inhibitor]] with a wide range of actions, primarily noted for its anti-inflammatory effects. It inhibits [[phosphodiesterase-4]] (PDE4) and -10 (PDE10) and macrophage migration inhibitory factor (MIF). This makes it a candidate for the treatment of conditions like [[asthma]], [[multiple sclerosis]], and certain types of [[pain management|pain]]. Ibudilast crosses the [[blood-brain barrier]], which makes it a potential treatment for neurodegenerative diseases.
+{{Short description|A phosphodiesterase inhibitor used in the treatment of neurological disorders}}
+{{Drugbox
+| verifiedfields = changed
+| verifiedrevid = 477002123
+| image = Ibudilast.svg
+| image_size = 200px
+| image_alt = Structural formula of Ibudilast
+}}
-==Medical Uses==
+'''Ibudilast''' is a [[phosphodiesterase inhibitor]] that has been investigated for its potential use in treating various [[neurological disorders]]. It is known for its anti-inflammatory and neuroprotective properties.
-Ibudilast has been used in Japan and South Korea since the early 1980s for the treatment of asthma and post-stroke complications. Its anti-inflammatory properties have led to research into its effectiveness in treating a variety of diseases characterized by inflammation or neurodegeneration, such as multiple sclerosis (MS), [[chronic obstructive pulmonary disease]] (COPD), and [[neuropathic pain]].
+==Mechanism of Action==
+Ibudilast works primarily by inhibiting the activity of [[phosphodiesterase]] (PDE) enzymes, particularly PDE-4 and PDE-10. This inhibition leads to an increase in intracellular levels of [[cyclic adenosine monophosphate]] (cAMP) and [[cyclic guanosine monophosphate]] (cGMP), which are important secondary messengers in cellular signaling pathways. By modulating these pathways, ibudilast exerts its anti-inflammatory and neuroprotective effects.
+==Therapeutic Uses==
+Ibudilast has been studied for its potential benefits in several neurological conditions, including:
 ===Multiple Sclerosis===
-In multiple sclerosis, ibudilast is believed to reduce [[neuroinflammation]] and protect against [[neurodegeneration]], potentially slowing the progression of the disease. Clinical trials have shown it to be effective in reducing the rate of brain atrophy in patients with progressive MS.
+Ibudilast has shown promise in the treatment of [[multiple sclerosis]] (MS), a chronic autoimmune disease that affects the central nervous system. It may help reduce inflammation and slow the progression of the disease.
-===Pain Management===
+===Neuropathic Pain===
-Ibudilast has shown promise in the treatment of neuropathic pain, where traditional pain management strategies are often ineffective. Its mechanism of action includes the inhibition of pro-inflammatory cytokines and the promotion of anti-inflammatory cytokines, which can help in reducing pain.
+The drug has also been investigated for its ability to alleviate [[neuropathic pain]], which is pain caused by damage to the nervous system. Its anti-inflammatory properties may help reduce pain and improve quality of life for patients.
-==Mechanism of Action==
+===Drug Addiction===
-Ibudilast's primary mechanism is the inhibition of phosphodiesterase-4 and -10, which leads to an increase in intracellular [[cAMP]] and [[cGMP]]. These second messengers play a crucial role in the regulation of immune responses and neuroprotection. By increasing their levels, ibudilast exerts anti-inflammatory and neuroprotective effects. Additionally, its inhibition of macrophage migration inhibitory factor (MIF) further contributes to its anti-inflammatory properties.
+Research has explored the use of ibudilast in treating [[drug addiction]], particularly for substances such as [[methamphetamine]] and [[opioids]]. It may help reduce cravings and withdrawal symptoms.
-==Adverse Effects==
+==Side Effects==
-The most common adverse effects of ibudilast include gastrointestinal symptoms such as nausea and diarrhea, as well as headaches and dizziness. Due to its ability to cross the blood-brain barrier, it may also cause psychiatric symptoms in some patients, such as depression and anxiety.
+Common side effects of ibudilast include [[nausea]], [[headache]], and [[dizziness]]. More serious side effects are rare but can include [[liver dysfunction]] and [[allergic reactions]].
 ==Pharmacokinetics==
-Ibudilast is well absorbed orally with a bioavailability of approximately 40%. It is metabolized in the liver and excreted primarily in the urine. Its half-life is around 10-12 hours, allowing for twice-daily dosing in most therapeutic applications.
+Ibudilast is administered orally and is well absorbed from the gastrointestinal tract. It is metabolized in the liver and excreted primarily in the urine. The drug has a half-life of approximately 19 hours, allowing for once or twice daily dosing.
-==Research==
+==Research and Development==
-Ongoing research is exploring the potential of ibudilast in treating other conditions, including drug addiction, particularly in reducing withdrawal symptoms and preventing relapse in opioid and methamphetamine dependence. Its neuroprotective properties are also being investigated in the context of other neurodegenerative diseases like [[Parkinson's disease]] and [[Alzheimer's disease]].
+Ongoing research is exploring the full potential of ibudilast in various neurological and inflammatory conditions. Clinical trials are being conducted to better understand its efficacy and safety profile.
-==Conclusion==
+==Related pages==
-Ibudilast represents a promising therapeutic agent due to its broad mechanism of action, offering potential benefits in the treatment of various inflammatory and neurodegenerative diseases. However, further research and clinical trials are necessary to fully understand its efficacy and safety profile in these conditions.
+* [[Phosphodiesterase inhibitor]]
+* [[Multiple sclerosis]]
+* [[Neuropathic pain]]
+* [[Drug addiction]]
 [[Category:Phosphodiesterase inhibitors]]
+[[Category:Neurology]]
 [[Category:Anti-inflammatory agents]]
-[[Category:Drugs used in neurodegenerative diseases]]
-[[Category:Medicinal chemistry]]
-{{Pharmacology-stub}}
-{{Medicine-stub}}